Name: 글로벌 시장 동향
SKU: PH740
Availability: InStock

보고서 요약(국문)

백신 시장 개요
백신 시장은 예측 기간(2023-2030년) 동안 연평균 5.8%의 성장률을 기록할 것으로 예상됩니다. 백신은 인체의 면역 체계를 훈련시켜 이전에 접촉한 적이 없는 질병과 싸우도록 하는 의약품의 일종입니다. 백신은 질병 예방을 위해 개발되었으며, 환자가 특정 질병에 대한 면역력을 갖게 되면 해당 질병으로부터 보호받게 됩니다. 대부분의 백신은 정맥 주사로 투여되지만, 일부는 경구 또는 비강 투여 방식으로 투여됩니다.
백신 시장 동향 및 추세
백신 시장 성장은 결핵, 코로나19와 같은 감염병 등 다양한 질병의 유병률 증가, 질병 예방을 위한 백신 접종 증가, 고령 인구 증가, 그리고 연구 개발 활동 증가에 의해 주도되고 있습니다.
백신 개발 증가는 시장 성장을 견인할 것으로 예상됩니다.
결핵 및 감염병과 같은 다양한 질병 환자 수의 증가는 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다. 2020년 면역학 저널에 발표된 논문에 따르면, 오늘날 사용되는 대부분의 백신은 생백신법과 같은 다양한 방법을 통해 개발되었습니다. 백신 개발 기술, 특히 재조합 기술의 발전 덕분에 이러한 개발이 가능해졌습니다. 예를 들어, 현재 사용 가능한 B형 간염 백신은 HBsAg 유전자를 효모에 클로닝하여 효모 세포 내에서 HBsAg를 합성하는 방식으로 생산됩니다. 또한, 새로운 기술에는 주요 항원을 암호화하는 핵산을 사용하는 것도 포함됩니다. DNA 주입 후 나중에 단백질을 투여하는 방식을 결합하면 감염성 병원체를 생성할 위험 없이 항원을 생산할 수 있습니다.
더불어, 감염병의 확산이 둔화됨에 따라 시장 참여자들은 새로운 제품 개발과 백신 출시에도 박차를 가하고 있습니다. 예를 들어, 2021년 7월 GSK는 면역결핍 또는 알려진 질병이나 치료로 인한 면역억제로 인해 대상포진 발병 위험이 높거나 높을 것으로 예상되는 18세 이상 성인의 대상포진 예방을 위한 Shingrix(대상포진 재조합 백신, 보조제 함유)에 대해 미국 FDA 승인을 받았습니다. 또한, 2021년 6월 Merck는 Sanofi Pasteur와 공동 개발한 VAXELIS(디프테리아 및 파상풍 톡소이드, 무세포 백일해, 불활성화 소아마비 바이러스, 헤모필루스 b 접합체 및 B형 간염 백신)를 미국에서 출시했습니다.
백신의 부작용은 시장 성장을 저해할 수 있습니다.
그러나 백신의 부작용은 백신 종류에 따라 다릅니다. 예를 들어, DTaP 백신 접종 후 부작용으로는 주사 부위의 통증이나 부기, 발열, 보챔, 식욕 부진, 피로, 구토 등이 있습니다. 인플루엔자 생백신의 경우, 구토, 근육통, 발열, 인후통, 기침 등이 발생할 수 있는 부작용입니다. 이러한 부작용은 시장 성장을 저해하는 요인으로 작용하고 있습니다.
코로나19가 백신 시장에 미치는 영향 분석
코로나19의 출현은 전 세계 백신 시장에 긍정적인 영향을 미쳤습니다. 코로나바이러스 감염을 예방하기 위해 주요 기업들은 코로나19 백신 연구 개발에 착수했습니다. 백신 개발 과정에서 관련 업계는 엄격한 프로토콜을 준수해야 합니다. 미국 질병통제예방센터(CDC)의 2022년 7월 보고서에 따르면, 새로운 백신이 대중에게 보급되기까지는 백신 개발, 임상 시험, 미국 식품의약국(FDA) 승인, 생산 및 유통 등 여러 단계를 거쳐야 합니다.
또한, 수많은 공공 및 민간 기관들이 협력하여 일반 대중이 코로나19 백신 접종을 받을 수 있도록 노력하고 있습니다. 예를 들어, 2020년 4월 아스트라제네카와 옥스퍼드 대학교는 SARS-CoV-2로 인한 COVID-19 감염 예방을 목표로 하는 옥스퍼드 대학교의 재조합 아데노바이러스 백신 후보 물질의 전 세계 개발 및 유통을 위해 협력했습니다. 또한, 2020년 12월에는 인도의 바라트 바이오테크(Bharat Biotech)가 인도 의학연구위원회(ICMR) 산하 국립 바이러스 연구소(NIV)와 협력하여 인도의 자체 개발 COVID-19 백신인 코백신(COVAXIN)을 개발했습니다.
이 외에도, 2022년 1월 현재 전 세계적으로 약 137개의 COVID-19 백신 후보 물질이 임상 시험 단계에 있으며, 194개의 후보 물질이 전임상 개발 단계에 있습니다. 전반적으로 COVID-19는 백신 시장에 긍정적인 영향을 미쳤습니다.
백신 시장 세분화 분석
COVID-19 질병 부문은 예측 기간(2022-2029년) 동안 가장 빠른 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다.
COVID-19 질병 부문은 예측 기간 동안 시장 성장을 견인할 것으로 전망됩니다. 코로나바이러스 감염 확산으로 COVID-19 감염 환자가 증가하면서, 시장 참여자들은 새로운 치료제를 개발하여 전 세계적인 감염 확산을 최소화할 수 있는 기회를 맞이했습니다. 예를 들어, 2022년 1월 화이자(Pfizer Inc.)와 바이오엔텍(BioNTech SE)은 18세에서 55세 성인을 대상으로 오미크론(Omicron) 기반 백신 후보 물질의 안전성, 면역원성 및 내약성을 평가하는 임상 연구를 시작했습니다. 또한, 2021년 12월 인도세럼연구소(SII)는 향후 6개월 내에 어린이용 COVID-19 백신을 출시할 계획을 발표했습니다. 이러한 제품 출시는 회사의 사업 실적에 긍정적인 영향을 미칠 것으로 예상됩니다.
더불어, 일부 시장 참여자들은 사업 확장을 위해 협력 및 인수 전략을 채택하고 있습니다. 예를 들어, 머크(Merck)는 2020년 6월 홍역 벡터 기반 COVID-19 백신 개발을 위해 테미스(Themis)를 인수했습니다. 이는 새로운 기술과 전문 지식의 도입으로 백신 개발 잠재력을 더욱 활성화시켰습니다.

백신 시장 지역별 점유율
북미 지역은 전 세계 백신 시장에서 가장 큰 시장 점유율을 차지하고 있습니다.
북미는 백신 시장을 주도하고 있으며, 예측 기간 동안에도 이러한 추세가 지속될 것으로 예상됩니다. 질병 발생률 증가, 선진 의료 시스템, 고령 인구 증가, 연구 개발 활동, 그리고 다수의 생명공학 기업 덕분에 예측 기간(2022-2029년) 동안 북미 지역은 상당한 시장 규모를 유지할 것으로 전망됩니다. 제품 개발 및 백신 제품 승인이 북미 지역 시장 성장을 견인하고 있습니다. 2022년 7월, 미국 식품의약국(FDA)은 12세 이상을 대상으로 NVX-CoV2373(노바백스 코로나19 백신)에 대한 긴급 사용 승인을 내렸고, 이후 미국 질병통제예방센터(CDC)도 이를 코로나19 백신 접종 옵션으로 제안했습니다.
또한, 시장 참여 기업들은 신제품 출시 및 협력 등 다양한 시장 전략을 활용하고 있습니다. 예를 들어, 2020년 4월 미국 식품의약국(FDA)은 사노피의 멘쿼피(MenQuadfi) 백신을 2세 이상 성인의 침습성 수막구균 질환 예방용으로 승인했습니다. 또한, 2021년에는 머크 샤프앤도메인의 완전 자회사인 MSD 파마슈티컬스가 인도 최초의 성별 중립 HPV 백신인 가다실 9(Gardasil 9)를 출시했습니다.
백신 기업 및 경쟁 환경
백신 시장은 국내외 기업들이 경쟁하는 비교적 경쟁적인 시장입니다. 시장 성장에 기여하는 주요 기업으로는 머크앤코, 에머전트 바이오 솔루션, 글락소스미스클라인, 노바티스, 사노피 파스퇴르, 시퀴러스, 화이자, CSL, 존슨앤존슨, 세럼 인스티튜트 오브 인디아 등이 있습니다. 주요 기업들은 신제품 출시, 인수, 협력 등 다양한 성장 전략을 채택하고 있으며, 이는 전 세계 백신 시장 성장에 기여하고 있습니다.

예를 들어,
• 2021년 10월, 화이자는 5세에서 11세 아동을 위한 화이자-바이오엔텍 코로나19 백신에 대해 미국 FDA의 긴급사용승인(EUA)을 받았습니다.

• 2021년 8월, 화이자-바이오엔텍 코로나19 백신 코미네이티(COMIRNATY)는 16세 이상 성인을 대상으로 미국 FDA의 정식 승인을 받았습니다.
머크앤컴퍼니(Merck & Co., Inc.)
개요:
머크앤컴퍼니는 1891년에 설립되어 미국에 본사를 둔 미국의 다국적 제약 회사입니다. 전 세계적으로 질병 예방을 위한 백신을 연구, 개발 및 유통하고 있습니다.
치료 유형 포트폴리오:
BCG 백신: 이 백신은 경피 접종용 생백신입니다. 결핵(TB) 치료에 사용됩니다. 결핵은 결핵균(Mycobacterium tuberculosis)에 의해 발생하는 공기 전염성 질병입니다.
글로벌 백신 시장 보고서는 약 70개 이상의 시장 데이터 표, 70개 이상의 그림, 그리고 약 250페이지 분량의 자료를 제공합니다.

보고서 요약(영어 원문)

Vaccines Market Overview
Vaccines Market is estimated to reach at a CAGR of 5.8% during the forecast period (2023-2030). A vaccine is a type of medicine that trains the body’s immune system to fight diseases it has not come into contact with before. Vaccines are developed to prevent disease; when patients are immune to a disease, they are protected against it. Most vaccines are given intravenously, but some are given orally or nasally.
Vaccines Market Dynamics and Trends
The vaccines market growth is driven by the rise in prevalence of different diseases such as tuberculosis, infectious diseases such as COVID-19, rising adoption of vaccines to prevent diseases, an increase in the geriatric population, and research and development activities.
The rising development of vaccines is expected to drive the market growth
The rising number of patients with different diseases, such as tuberculosis and infectious diseases, is expected to boost the market over the forecast period. As the article published in Immunization in 2020, most vaccines used nowadays have been developed by different methods, such as the live-attenuated method. Due to the advancement of the techniques of vaccine development, especially recombinant techniques. For instance, available hepatitis B vaccines are currently produced by cloning the HBsAg gene into yeast, leading to the synthesis of HBsAg within the yeast cell. Also, new technologies include the use of nucleic acids, which encode critical antigens. The combination of DNA injection with the administration of protein at a later point in time leads to the production of antigens without the risk of producing whole infectious organisms.
In addition, with the breakdown of infectious diseases, the market players are engaged in new product development and launching vaccines. For instance, in July 2021, GSK received US FDA approval for Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 18 years and older who are or will be at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy. Also, in June 2021, Merck launched the VAXELIS (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine) in the United States, developed in partnership with Sanofi Pasteur.
The side effects of vaccines will hamper the growth of the market
However, the side effects of vaccines vary with different vaccines. For instance, after DTaP vaccination, the side effects include soreness or swelling where the shot was given, fever, fussiness, loss of appetite, tiredness, and vomiting. In the case of Influenza live vaccine, vomiting, muscle aches, fever, sore throat, and cough are other possible side effects. These side effects are limiting the market growth.
COVID-19 Impact Analysis on Vaccines Market
The appearance of COVID-19 positively impacted the global vaccines market. To prevent the coronavirus infection, the key players are started the research and development of vaccines for COVID-19. While developing a vaccine, industries have to follow the protocol, which is quite difficult. As per the data of the CDC July 2022 report, a novel vaccine's introduction to the public involves several processes, including vaccine development, clinical testing, permission or approval by the U.S. Food and Drug Administration (FDA), production, and distribution.
In addition, numerous public and private institutions have collaborated to make COVID-19 vaccinations accessible to the general public. For instance, in April 2020, AstraZeneca and the University of Oxford collaborated on the global development and distribution of the University's potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2. Also, in December 2020, COVAXIN India's indigenous COVID-19 vaccine by Bharat Biotech was developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV).
In addition, as of January 2022, there are around 137 COVID-19 vaccine candidates undergoing clinical trials and 194 candidates in pre-clinical development worldwide. Overall the impact of COVID-19 positively affected the vaccine market.
Vaccines Market Segmentation Analysis
The COVID-19 disease segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The COVID-19 disease segment is expected to boost the market over the period of the forecast. Due to the outbreak of coronavirus infection, more patients were getting infected by the COVID-19 infection, which opens the opportunity for the market players to develop a new drug and help to minimize the infection worldwide. For instance, in January 2022, Pfizer Inc. and BioNTech SE started a clinical study to evaluate the safety, immunogenicity, and tolerability of an Omicron-based vaccine candidate in adults aged 18 to 55. Also, in December 2021, the Serum Institute of India (SII) declared its plan to launch a COVID vaccine for children in the coming six months. This product launch will benefit the company’s business performance.
Moreover, some market players are adopting collaboration and acquisition market strategies to expand their business. For instance, in June 2020, Merck acquired the Themis for the development of a measles vector-based COVID-19 vaccine. This has stimulated the vaccine development potential with the addition of new technology and expertise.
Vaccines Market Geographical Share
North America region holds the largest market share of the global vaccines market
North America dominates the market for vaccines and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the increased population with disease, advanced healthcare system, growing geriatric population, research and development activities and a large number of biotechnological companies. Development of products and approval of vaccine products drives the market in the North American region. In July 2022, the US Food and Drug Administration issued an emergency use authorization for NVX-CoV2373 (Novavax COVID-19 vaccine) for individuals aged 12 years or older, and the Centers for Disease Control and Prevention subsequently suggested it as an option for COVID-19 vaccination.
Moreover, the market players are applying different market strategies such as product launching and collaboration. For instance, in April 2020, the U.S. Food and Drug Administration (FDA) approved Sanofi’s MenQuadfi vaccine for the prevention of invasive meningococcal diseases in persons aged 2 years and older. Also, in 2021, MSD Pharmaceuticals, a wholly-owned subsidiary of Merck Sharp & Dohme, launched “Gardasil 9”, India’s first gender-neutral HPV vaccine.
Vaccines Companies and Competitive Landscape
The vaccines market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Merck & Co., Inc, Emergent Bio solutions, GlaxoSmithKline, Novartis, Sanofi Pasteur, Seqirus, Pfizer, CSL Limited, Jhonson & Jhonson, and Serum Institute of India Pvt Ltd. among others. The major players are adopting several growth strategies such as new product launches, acquisitions, and collaborations, which are contributing to the growth of the vaccines market globally.
For instance,
• In October 2021, Pfizer received the US FDA Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age.
• In August 2021, Pfizer-BioNTech COVID-19 vaccine COMIRNATY received full US FDA approval for individuals 16 years and older.
Merck & Co., Inc
Overview:
Merck & Co., Inc. is an American multinational pharmaceutical company founded in 1891 and headquartered in the United States. It is discovering, developing and distributing vaccines to prevent the disease worldwide.
Treatment type Portfolio:
BCG Vaccine: This vaccine is used as live attenuated for percutaneous use. It used for the treatment of tuberculosis (TB), an airborne communicable disease caused by bacterium mycobacterium tuberculosis.
The global vaccines market report would provide access to approximately 70+ market data tables, 70+ figures, and in the range of 250+ (approximate) pages.

상세 목차

1. Market Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. High prevalence of chronic disease
4.1.1.2. Rising demand for infection control measure
4.1.2. Restraints:
4.1.2.1. Side Effects associated with vaccines
4.1.3. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
5.4. Pricing Analysis
5.5. Unmet Needs
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Vaccines Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccines Type Segment
7.1.2. Market Attractiveness Index, By Vaccines Type
7.2. Live-attenuated*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Inactivated
7.4. Conjugate
7.5. Toxoid
7.6. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Intravenous
8.4. Others
9. By Disease
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
9.1.2. Market Attractiveness Index, By Disease
9.2. Measles*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Influenza
9.4. Smallpox
9.5. Yellow fever
9.6. Hepatitis A
9.7. Polio
9.8. Shingles
9.9. COVID-19
9.10. Others
10. By Age
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Segment
10.1.2. Market Attractiveness Index, By Age Segment
10.2. Pediatrics*
10.2.1. Introduction
10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Adults
10.4. Geriatrics
11. By Distribution Channel
11.1. Introduction
11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
11.1.2. Market Attractiveness Index, By Distribution Channel Segment
11.2. Hospital Pharmacies*
11.2.1. Introduction
11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
11.3. Retail Pharmacies
11.4. Online Pharmacies
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccines Types
12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age
12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.2.8.1. The U.S.
12.2.8.2. Canada
12.2.8.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccines Types
12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age
12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.3.8.1. Germany
12.3.8.2. U.K.
12.3.8.3. France
12.3.8.4. Italy
12.3.8.5. Spain
12.3.8.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccines Types
12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age
12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.4.8.1. Brazil
12.4.8.2. Argentina
12.4.8.3. Rest of South America
12.5. Asia Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccines Types
12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age
12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
12.5.8.1. China
12.5.8.2. India
12.5.8.3. Japan
12.5.8.4. Australia
12.5.8.5. Rest of Asia Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccines Types
12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age
12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
13. Competitive Landscape
13.1. Key Developments and Strategies
13.2. Company Share Analysis
13.3. Treatment type Benchmarking
14. Company Profiles
14.1. Merck&Co., Inc*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Key Highlights
14.1.4. Financial Overview
14.2. Emergent Bio solutions
14.3. GlaxoSmithKline
14.4. Novartis
14.5. Sanofi Pasteur
14.6. Seqirus
14.7. Pfizer
14.8. CSL Limited
14.9. Jhonson & Jhonson
14.10. Serum Institute of India Pvt Ltd. (*LIST NOT EXHAUSTIVE)
15. DataM Intelligence
15.1. Appendix
15.2. About Us and Services
15.3. Contact US

언급된 주요 기업들

Merck&Co., Inc, Emergent Bio solutions, GlaxoSmithKline, Novartis, Sanofi Pasteur, Seqirus, Pfizer, CSL Limited, Jhonson & Jhonson

표 목록 (Tables)

List of Tables

Table 1 Global Vaccine Market Value, By Type, 2024, 2028 & 2032 (US$ Million)

Table 2 Global Vaccine Market Value, By Category, 2024, 2028 & 2032 (US$ Million)

Table 3 Global Vaccine Market Value, By Disease Indication, 2024, 2028 & 2032 (US$ Million)

Table 4 Global Vaccine Market Value, By Route of Administration, 2024, 2028 & 2032 (US$ Million)

Table 5 Global Vaccine Market Value, By End User, 2024, 2028 & 2032 (US$ Million)

Table 6 Global Vaccine Market Value, By Distribution Channel, 2024, 2028 & 2032 (US$ Million)

Table 7 Global Vaccine Market Value, By Region, 2024, 2028 & 2032 (US$ Million)

Table 8 Global Vaccine Market Value, By Type, 2024, 2028 & 2032 (US$ Million)

Table 9 Global Vaccine Market Value, By Type, 2023-2032 (US$ Million)

Table 10 Global Vaccine Market Value, By Category, 2024, 2028 & 2032 (US$ Million)

Table 11 Global Vaccine Market Value, By Category, 2023-2032 (US$ Million)

Table 12 Global Vaccine Market Value, By Disease Indication, 2024, 2028 & 2032 (US$ Million)

Table 13 Global Vaccine Market Value, By Disease Indication, 2023-2032 (US$ Million)

Table 14 Global Vaccine Market Value, By Route of Administration, 2024, 2028 & 2032 (US$ Million)

Table 15 Global Vaccine Market Value, By Route of Administration, 2023-2032 (US$ Million)

Table 16 Global Vaccine Market Value, By End User, 2024, 2028 & 2032 (US$ Million)

Table 17 Global Vaccine Market Value, By End User, 2023-2032 (US$ Million)

Table 18 Global Vaccine Market Value, By Distribution Channel, 2024, 2028 & 2032 (US$ Million)

Table 19 Global Vaccine Market Value, By Distribution Channel, 2023-2032 (US$ Million)

Table 20 Global Vaccine Market Value, By Region, 2024, 2028 & 2032 (US$ Million)

Table 21 Global Vaccine Market Value, By Region, 2023-2032 (US$ Million)

Table 22 North America Vaccine Market Value, By Type, 2023-2032 (US$ Million)

Table 23 North America Vaccine Market Value, By Category, 2023-2032 (US$ Million)

Table 24 North America Vaccine Market Value, By Disease Indication, 2023-2032 (US$ Million)

Table 25 North America Vaccine Market Value, By Route of Administration, 2023-2032 (US$ Million)

Table 26 North America Vaccine Market Value, By End User, 2023-2032 (US$ Million)

Table 27 North America Vaccine Market Value, By Distribution Channel, 2023-2032 (US$ Million)

Table 28 North America Vaccine Market Value, By Country, 2023-2032 (US$ Million)

Table 29 Asia-Pacific Vaccine Market Value, By Type, 2023-2032 (US$ Million)

Table 30 Asia-Pacific Vaccine Market Value, By Category, 2023-2032 (US$ Million)

Table 31 Asia-Pacific Vaccine Market Value, By Disease Indication, 2023-2032 (US$ Million)

Table 32 Asia-Pacific Vaccine Market Value, By Route of Administration, 2023-2032 (US$ Million)

Table 33 Asia-Pacific Vaccine Market Value, By End User, 2023-2032 (US$ Million)

Table 34 Asia-Pacific Vaccine Market Value, By Distribution Channel, 2023-2032 (US$ Million)

Table 35 Asia-Pacific Vaccine Market Value, By Country, 2023-2032 (US$ Million)

Table 36 Europe Vaccine Market Value, By Type, 2023-2032 (US$ Million)

Table 37 Europe Vaccine Market Value, By Category, 2023-2032 (US$ Million)

Table 38 Europe Vaccine Market Value, By Disease Indication, 2023-2032 (US$ Million)

Table 39 Europe Vaccine Market Value, By Route of Administration, 2023-2032 (US$ Million)

Table 40 Europe Vaccine Market Value, By End User, 2023-2032 (US$ Million)

Table 41 Europe Vaccine Market Value, By Distribution Channel, 2023-2032 (US$ Million)

Table 42 Europe Vaccine Market Value, By Country, 2023-2032 (US$ Million)

Table 43 South America Vaccine Market Value, By Type, 2023-2032 (US$ Million)

Table 44 South America Vaccine Market Value, By Category, 2023-2032 (US$ Million)

Table 45 South America Vaccine Market Value, By Disease Indication, 2023-2032 (US$ Million)

Table 46 South America Vaccine Market Value, By Route of Administration, 2023-2032 (US$ Million)

Table 47 South America Vaccine Market Value, By End User, 2023-2032 (US$ Million)

Table 48 South America Vaccine Market Value, By Distribution Channel, 2023-2032 (US$ Million)

Table 49 South America Vaccine Market Value, By Country, 2023-2032 (US$ Million)

Table 50 Middle East and Africa Vaccine Market Value, By Type, 2023-2032 (US$ Million)

Table 51 Middle East and Africa Vaccine Market Value, By Category, 2023-2032 (US$ Million)

Table 52 Middle East and Africa Vaccine Market Value, By Disease Indication, 2023-2032 (US$ Million)

Table 53 Middle East and Africa Vaccine Market Value, By Route of Administration, 2023-2032 (US$ Million)

Table 54 Middle East and Africa Vaccine Market Value, By End User, 2023-2032 (US$ Million)

Table 55 Middle East and Africa Vaccine Market Value, By Distribution Channel, 2023-2032 (US$ Million)

Table 56 Middle East and Africa Vaccine Market Value, By Country, 2023-2032 (US$ Million)

Table 57 GSK plc.: Overview

Table 58 GSK plc.: Product Portfolio

Table 59 GSK plc.: Key Developments

Table 60 Merck & Co., Inc.: Overview

Table 61 Merck & Co., Inc.: Product Portfolio

Table 62 Merck & Co., Inc.: Key Developments

Table 63 Pfizer Inc. : Overview

Table 64 Pfizer Inc. : Product Portfolio

Table 65 Pfizer Inc. : Key Developments

Table 66 CSL: Overview

Table 67 CSL: Product Portfolio

Table 68 CSL: Key Developments

Table 69 EMERGENT : Overview

Table 70 EMERGENT : Product Portfolio

Table 71 EMERGENT : Key Developments

Table 72 Johnson & Johnson Services, Inc.: Overview

Table 73 Johnson & Johnson Services, Inc.: Product Portfolio

Table 74 Johnson & Johnson Services, Inc.: Key Developments

Table 75 AstraZeneca : Overview

Table 76 AstraZeneca : Product Portfolio

Table 77 AstraZeneca : Key Developments

Table 78 Bavarian Nordic: Overview

Table 79 Bavarian Nordic: Product Portfolio

Table 80 Bavarian Nordic: Key Developments

Table 81 Bharat Biotech : Overview

Table 82 Bharat Biotech : Product Portfolio

Table 83 Bharat Biotech : Key Developments

Table 84 Serum Institute of India Pvt. Ltd.: Overview

Table 85 Serum Institute of India Pvt. Ltd.: Product Portfolio

Table 86 Serum Institute of India Pvt. Ltd.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 2 Global Vaccine Market Share, By Type, 2024 & 2032 (%)

Figure 3 Global Vaccine Market Share, By Category, 2024 & 2032 (%)

Figure 4 Global Vaccine Market Share, By Disease Indication, 2024 & 2032 (%)

Figure 5 Global Vaccine Market Share, By Route of Administration, 2024 & 2032 (%)

Figure 6 Global Vaccine Market Share, By End User, 2024 & 2032 (%)

Figure 7 Global Vaccine Market Share, By Distribution Channel, 2024 & 2032 (%)

Figure 8 Global Vaccine Market Share, By Region, 2024 & 2032 (%)

Figure 9 Global Vaccine Market Y-o-Y Growth, By Type, 2024-2032 (%)

Figure 10 Conjugate Vaccines Vaccine Market Value, 2023-2032 (US$ Million)

Figure 11 Inactivated Vaccines Vaccine Market Value, 2023-2032 (US$ Million)

Figure 12 Live-attenuated Vaccines Vaccine Market Value, 2023-2032 (US$ Million)

Figure 13 Recombinant Vaccines Vaccine Market Value, 2023-2032 (US$ Million)

Figure 14 Toxoid Vaccines Vaccine Market Value, 2023-2032 (US$ Million)

Figure 15 Viral Vector Vaccines Vaccine Market Value, 2023-2032 (US$ Million)

Figure 16 Others Vaccine Market Value, 2023-2032 (US$ Million)

Figure 17 Global Vaccine Market Y-o-Y Growth, By Category, 2024-2032 (%)

Figure 18 Monovalent Vaccines Category in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 19 Bivalent Vaccines Category in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 20 Multivalent Vaccines Category in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 21 Global Vaccine Market Y-o-Y Growth, By Disease Indication, 2024-2032 (%)

Figure 22 Chickenpox Disease Indication in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 23 Cholera Disease Indication in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 24 Diphtheria Disease Indication in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 25 Influenza Disease Indication in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 26 Hepatitis Disease Indication in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 27 Measles Disease Indication in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 28 Mumps Disease Indication in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 29 Polio Disease Indication in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 30 Rabies Disease Indication in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 31 Others Disease Indication in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 32 Global Vaccine Market Y-o-Y Growth, By Route of Administration, 2024-2032 (%)

Figure 33 Intramuscular Route of Administration in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 34 Subcutaneous Route of Administration in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 35 Intranasal Route of Administration in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 36 Others Route of Administration in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 37 Global Vaccine Market Y-o-Y Growth, By End User, 2024-2032 (%)

Figure 38 Community Hospitals End User in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 39 Hospitals End User in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 40 Specialty Centers End User in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 41 Clinics End User in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 42 Others End User in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 43 Global Vaccine Market Y-o-Y Growth, By Distribution Channel, 2024-2032 (%)

Figure 44 Hospital Pharmacy Distribution Channel in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 45 Retail Pharmacy Distribution Channel in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 46 Online Pharmacy Distribution Channel in Global Vaccine Market Value, 2023-2032 (US$ Million)

Figure 47 Global Vaccine Market Y-o-Y Growth, By Region, 2024-2032 (%)

Figure 48 North America Vaccine Market Value, 2023-2032 (US$ Million)

Figure 49 North America Vaccine Market Share, By Type, 2024 & 2032 (%)

Figure 50 North America Vaccine Market Share, By Category, 2024 & 2032 (%)

Figure 51 North America Vaccine Market Share, By Disease Indication, 2024 & 2032 (%)

Figure 52 North America Vaccine Market Share, By Route of Administration, 2024 & 2032 (%)

Figure 53 North America Vaccine Market Share, By End User, 2024 & 2032 (%)

Figure 54 North America Vaccine Market Share, By Distribution Channel, 2024 & 2032 (%)

Figure 55 North America Vaccine Market Share, By Country, 2024 & 2032 (%)

Figure 56 Asia-Pacific Vaccine Market Value, 2023-2032 (US$ Million)

Figure 57 Asia-Pacific Vaccine Market Share, By Type, 2024 & 2032 (%)

Figure 58 Asia-Pacific Vaccine Market Share, By Category, 2024 & 2032 (%)

Figure 59 Asia-Pacific Vaccine Market Share, By Disease Indication, 2024 & 2032 (%)

Figure 60 Asia-Pacific Vaccine Market Share, By Route of Administration, 2024 & 2032 (%)

Figure 61 Asia-Pacific Vaccine Market Share, By End User, 2024 & 2032 (%)

Figure 62 Asia-Pacific Vaccine Market Share, By Distribution Channel, 2024 & 2032 (%)

Figure 63 Asia-Pacific Vaccine Market Share, By Country, 2024 & 2032 (%)

Figure 64 Europe Vaccine Market Value, 2023-2032 (US$ Million)

Figure 65 Europe Vaccine Market Share, By Type, 2024 & 2032 (%)

Figure 66 Europe Vaccine Market Share, By Category, 2024 & 2032 (%)

Figure 67 Europe Vaccine Market Share, By Disease Indication, 2024 & 2032 (%)

Figure 68 Europe Vaccine Market Share, By Route of Administration, 2024 & 2032 (%)

Figure 69 Europe Vaccine Market Share, By End User, 2024 & 2032 (%)

Figure 70 Europe Vaccine Market Share, By Distribution Channel, 2024 & 2032 (%)

Figure 71 Europe Vaccine Market Share, By Country, 2024 & 2032 (%)

Figure 72 South America Vaccine Market Value, 2023-2032 (US$ Million)

Figure 73 South America Vaccine Market Share, By Type, 2024 & 2032 (%)

Figure 74 South America Vaccine Market Share, By Category, 2024 & 2032 (%)

Figure 75 South America Vaccine Market Share, By Disease Indication, 2024 & 2032 (%)

Figure 76 South America Vaccine Market Share, By Route of Administration, 2024 & 2032 (%)

Figure 77 South America Vaccine Market Share, By End User, 2024 & 2032 (%)

Figure 78 South America Vaccine Market Share, By Distribution Channel, 2024 & 2032 (%)

Figure 79 South America Vaccine Market Share, By Country, 2024 & 2032 (%)

Figure 80 Middle East and Africa Vaccine Market Value, 2023-2032 (US$ Million)

Figure 81 Middle East and Africa Vaccine Market Share, By Type, 2024 & 2032 (%)

Figure 82 Middle East and Africa Vaccine Market Share, By Category, 2024 & 2032 (%)

Figure 83 Middle East and Africa Vaccine Market Share, By Disease Indication, 2024 & 2032 (%)

Figure 84 Middle East and Africa Vaccine Market Share, By Route of Administration, 2024 & 2032 (%)

Figure 85 Middle East and Africa Vaccine Market Share, By End User, 2024 & 2032 (%)

Figure 86 Middle East and Africa Vaccine Market Share, By Distribution Channel, 2024 & 2032 (%)

Figure 87 GSK plc.: Financials

Figure 88 Merck & Co., Inc.: Financials

Figure 89 Pfizer Inc. : Financials

Figure 90 CSL: Financials

Figure 91 EMERGENT : Financials

Figure 92 Johnson & Johnson Services, Inc.: Financials

Figure 93 AstraZeneca : Financials

Figure 94 Bavarian Nordic: Financials

Figure 95 Bharat Biotech : Financials

Figure 96 Serum Institute of India Pvt. Ltd.: Financials